MA30719B1 - Nouveaux derives d'aminopyridine ayant une action inhibitrice selective sur aurora a. - Google Patents

Nouveaux derives d'aminopyridine ayant une action inhibitrice selective sur aurora a.

Info

Publication number
MA30719B1
MA30719B1 MA31731A MA31731A MA30719B1 MA 30719 B1 MA30719 B1 MA 30719B1 MA 31731 A MA31731 A MA 31731A MA 31731 A MA31731 A MA 31731A MA 30719 B1 MA30719 B1 MA 30719B1
Authority
MA
Morocco
Prior art keywords
aurora
inhibitory action
selective inhibitory
aminopyridine derivatives
novel aminopyridine
Prior art date
Application number
MA31731A
Other languages
English (en)
Inventor
Yoshikazu Iwasawa
Tetsuya Kato
Nobuhiko Kawanishi
Kouta Masutani
Takashi Mita
Katsumasa Nonoshita
Mitsuru Ohkubo
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of MA30719B1 publication Critical patent/MA30719B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE GÉNÉRALE I : DANS LAQUELLE : R1 REPRÉSENTE UN ATOME D'HYDROGÈNE, F, CN, ETC. ; R2 REPRÉSENTE O, S, SO, SO2, ETC. ; R3 REPRÉSENTE UN PHÉNYLE QUI PEUT ÊTRE SUBSTITUÉ ; X2 REPRÉSENTE CH, N, ETC. ; W REPRÉSENTE LE RÉSIDU SUIVANT : DANS LEQUEL : W1, W2 ET W3 REPRÉSENTENT CHACUN INDÉPENDAMMENT CH, N, ETC., OU UN DE SES SELS OU ESTERS PHARMACEUTIQUEMENT ACCEPTABLES.
MA31731A 2006-08-31 2009-03-20 Nouveaux derives d'aminopyridine ayant une action inhibitrice selective sur aurora a. MA30719B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006236472 2006-08-31
US92608607P 2007-04-25 2007-04-25

Publications (1)

Publication Number Publication Date
MA30719B1 true MA30719B1 (fr) 2009-09-01

Family

ID=39136042

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31731A MA30719B1 (fr) 2006-08-31 2009-03-20 Nouveaux derives d'aminopyridine ayant une action inhibitrice selective sur aurora a.

Country Status (27)

Country Link
US (2) US7915263B2 (fr)
EP (2) EP2061782A4 (fr)
JP (3) JP2008081492A (fr)
KR (1) KR20090055562A (fr)
CN (1) CN101528731B (fr)
AR (1) AR062585A1 (fr)
AU (1) AU2007289609B2 (fr)
CA (1) CA2657469C (fr)
CL (1) CL2007002519A1 (fr)
CO (1) CO6190529A2 (fr)
CR (1) CR10553A (fr)
EC (1) ECSP099062A (fr)
ES (1) ES2389515T3 (fr)
GT (1) GT200900008A (fr)
HN (1) HN2009000113A (fr)
IL (1) IL196497A0 (fr)
MA (1) MA30719B1 (fr)
MX (1) MX2009000390A (fr)
NO (1) NO20091301L (fr)
NZ (1) NZ574081A (fr)
PE (1) PE20080835A1 (fr)
RU (1) RU2437880C2 (fr)
SV (1) SV2009003152A (fr)
TW (1) TW200817363A (fr)
UA (1) UA95972C2 (fr)
WO (2) WO2008026768A1 (fr)
ZA (1) ZA200900126B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009216062B2 (en) * 2008-02-22 2013-02-07 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
WO2009122436A2 (fr) * 2008-03-31 2009-10-08 Sun Pharmaceutical Industries Ltd. Procédé perfectionné pour la préparation d'analogues de morphinane
WO2010009985A2 (fr) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Combinaison thérapeutique renfermant un inhibiteur de la kinase aurora et des agents antiprolifératifs
KR101906146B1 (ko) * 2009-08-17 2018-10-10 메모리얼 슬로안-케터링 캔서 센터 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
WO2013047813A1 (fr) 2011-09-30 2013-04-04 大鵬薬品工業株式会社 Dérivé de 1,2,4-triazine-6-carboxamide
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
KR102461419B1 (ko) 2014-05-13 2022-11-02 메모리얼 슬로안 케터링 캔서 센터 Hsp70 조정물질 및 이의 제조 및 이용 방법
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光ａ激酶抑制劑
WO2016149922A1 (fr) * 2015-03-25 2016-09-29 Intel Corporation Procédé et appareil d'assurance de service informatique par grappes
CN108250191B (zh) * 2018-03-15 2020-10-20 兰州大学 一种3,5-二取代的2-氨基-吡嗪化合物及其制备工艺与应用
WO2020049208A1 (fr) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa comme cible pour traiter, prévenir ou soigner une infection par vih ou le sida
CN112898292A (zh) 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
CA3247183A1 (fr) 2022-04-08 2023-10-12 Eli Lilly And Company Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d’aurora a

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
SK283693B6 (sk) 1990-09-28 2003-12-02 Smithkline Beecham Corporation Spôsob prípravy kamptotecínu alebo jeho farmaceuticky prijateľnej soli
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
DE60023926T2 (de) * 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
EP1578341A2 (fr) 2000-10-11 2005-09-28 Tularik Inc. Modulation de fonction de ccr4
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
NZ526472A (en) * 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
RU2332415C2 (ru) * 2001-04-27 2008-08-27 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, полезные в качестве ингибиторов протеинкиназы
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
CN1956982A (zh) * 2004-05-21 2007-05-02 万有制药株式会社 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
EP1813609B1 (fr) * 2004-10-29 2013-06-19 Msd K.K. Nouveaux derives d'aminopyridine presentant un effet inhibiteur selectif d'aurora-a
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
WO2006053109A1 (fr) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Composes heteroaryle
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
CA2589830A1 (fr) 2005-01-05 2006-07-13 Rigel Pharmaceuticals, Inc. Inhibiteurs d'ubiquitine-ligases
AU2006241825A1 (en) * 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
WO2006124874A2 (fr) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
WO2006129842A1 (fr) * 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. Nouveau derive aminopyridine ayant une activite d’inhibition selective de l’aurora-a
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives

Also Published As

Publication number Publication date
CA2657469C (fr) 2013-07-02
CO6190529A2 (es) 2010-08-19
UA95972C2 (ru) 2011-09-26
WO2008026768A1 (fr) 2008-03-06
CR10553A (es) 2009-06-28
CL2007002519A1 (es) 2008-02-08
WO2008026769A1 (fr) 2008-03-06
JP2010047602A (ja) 2010-03-04
NZ574081A (en) 2011-08-26
AU2007289609A1 (en) 2008-03-06
CA2657469A1 (fr) 2008-03-06
NO20091301L (no) 2009-04-30
RU2437880C2 (ru) 2011-12-27
CN101528731B (zh) 2014-05-07
GT200900008A (es) 2010-10-04
ES2389515T3 (es) 2012-10-26
JPWO2008026769A1 (ja) 2010-01-21
EP2061782A4 (fr) 2010-03-31
JP4466782B2 (ja) 2010-05-26
AR062585A1 (es) 2008-11-19
EP2062887B1 (fr) 2012-07-04
CN101528731A (zh) 2009-09-09
ECSP099062A (es) 2009-02-27
AU2007289609B2 (en) 2012-02-02
HN2009000113A (es) 2014-01-06
US7915263B2 (en) 2011-03-29
EP2061782A1 (fr) 2009-05-27
JP5256168B2 (ja) 2013-08-07
PE20080835A1 (es) 2008-06-14
JP2008081492A (ja) 2008-04-10
KR20090055562A (ko) 2009-06-02
RU2009111599A (ru) 2010-10-10
SV2009003152A (es) 2009-04-28
IL196497A0 (en) 2009-09-22
ZA200900126B (en) 2010-01-27
EP2062887A1 (fr) 2009-05-27
MX2009000390A (es) 2009-01-29
US20080058347A1 (en) 2008-03-06
US20100016335A1 (en) 2010-01-21
TW200817363A (en) 2008-04-16
EP2062887A4 (fr) 2010-03-31

Similar Documents

Publication Publication Date Title
MA30719B1 (fr) Nouveaux derives d'aminopyridine ayant une action inhibitrice selective sur aurora a.
ECSP045414A (es) "pirazolpiridinas sustituidas con carbamato"
DK1751108T3 (da) Adamantyl-acetamidderivater som inhibitorer for 11-beta-hydroxysteroid-dehydrogenase-type 1-enzymet
NO20083480L (no) Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister
TN2010000053A1 (fr) Derives de bi cyclolactames substitues
MA30162B1 (fr) Nouveaux derives de pyrrole a cycles fusionnes
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
PH12013501663A1 (en) BYCYCLIC y-AMINO ACID DERIVATIVE
MX2007004699A (es) Derivados de indol y bencimidazol.
NO20054852L (no) GFAT inhibitorer
GB0505048D0 (en) Compounds with PGD antagonist activity
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
TN2010000173A1 (fr) Antagonistes de cgrp
MA29775B1 (fr) Derives de pyrazolone
WO2008139845A1 (fr) Nouveau dérivé amide
WO2007053844A3 (fr) Préparations et méthodes pour le traitement de troubles inflammatoires
MX2009008756A (es) Compuesto macrociclico.
HRP20080529T3 (en) Amide prodrug of gemcitabine, compositions and use thereof
ATE438398T1 (de) Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren
ZA200705474B (en) Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
FR2942797B1 (fr) Derives de benzothiazines, leur preparation et leur application a titre de medicaments
MA33320B1 (fr) Derives de rifamycine
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
NO20063944L (no) Piperidinylkarbonyl-pyrrolidiner og deres anvendelse som melanokortinagonister
NO20080165L (no) Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister